The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting.

immunotherapy single-cell analysis triple-negative breast cancer tumor microenvironment

Journal

Expert opinion on therapeutic targets
ISSN: 1744-7631
Titre abrégé: Expert Opin Ther Targets
Pays: England
ID NLM: 101127833

Informations de publication

Date de publication:
12 2022
Historique:
pmc-release: 29 01 2024
pubmed: 20 1 2023
medline: 7 2 2023
entrez: 19 1 2023
Statut: ppublish

Résumé

In contrast to other breast cancer subtypes, there are currently limited options of targeted therapies for triple-negative breast cancer (TNBC). Immense research has demonstrated that not only cancer cells but also stromal cells and immune cells in the tumor microenvironment (TME) play significant roles in the progression of TNBC. It is thus critical to understand the components of the TME of TNBC and the interactions between the various cell populations. The components of the TME of TNBC identified by single-cell technologies are reviewed. Furthermore, the molecular interactions between the cells and the potential therapeutic targets contributing to the progression of TNBC are discussed. Single-cell omics studies have contributed to the classification of cells in the TME and the identification of important cell types involved in the progression and the treatment of the tumor. The interactions between cancer cells and stromal cells/immune cells in the TME have led to the discovery of potential therapeutic targets. Experimental data with spatial and temporal resolution will further boost the understanding of the TME of TNBC.

Identifiants

pubmed: 36657483
doi: 10.1080/14728222.2022.2170779
pmc: PMC10189896
mid: NIHMS1871986
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1041-1056

Subventions

Organisme : NCI NIH HHS
ID : P30 CA006973
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA138264
Pays : United States

Références

Nat Commun. 2016 Oct 11;7:13050
pubmed: 27725631
Front Immunol. 2020 Feb 21;11:275
pubmed: 32153582
Cancer Inform. 2012;11:147-56
pubmed: 22872785
Cancer Med. 2016 Oct;5(10):2989-3006
pubmed: 27539549
Oncogene. 2021 May;40(18):3245-3259
pubmed: 33833397
Front Med (Lausanne). 2020 Feb 14;7:34
pubmed: 32118018
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Breast Cancer. 2021 Jul;28(4):904-914
pubmed: 33629216
Science. 2015 Nov 20;350(6263):985-90
pubmed: 26494174
Front Immunol. 2020 Feb 18;11:223
pubmed: 32133005
Nat Genet. 2013 Sep;45(9):970-6
pubmed: 23852170
Nat Rev Immunol. 2020 May;20(5):294-307
pubmed: 31988391
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Expert Rev Mol Med. 2015 Jan 30;17:e3
pubmed: 25634527
Cancer Res. 2011 Jun 1;71(11):4002-14
pubmed: 21632555
Arch Pharm Res. 2019 Jul;42(7):543-548
pubmed: 30859410
Nat Rev Genet. 2021 Oct;22(10):627-644
pubmed: 34145435
PLoS One. 2017 Jun 12;12(6):e0178173
pubmed: 28604807
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
Oncologist. 2010;15 Suppl 5:39-48
pubmed: 21138954
Nat Commun. 2018 Dec 4;9(1):5150
pubmed: 30514914
Immunity. 2014 Oct 16;41(4):529-42
pubmed: 25367570
Cell. 2021 Jul 22;184(15):3852-3872
pubmed: 34297930
Nat Cell Biol. 2019 Apr;21(4):498-510
pubmed: 30936474
Cancer Cell Int. 2022 Mar 5;22(1):108
pubmed: 35248028
Oncotarget. 2017 Dec 13;9(7):7398-7410
pubmed: 29484119
Breast Cancer Res Treat. 2020 Apr;180(2):369-377
pubmed: 32034580
Front Physiol. 2020 Oct 19;11:583333
pubmed: 33192595
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
NPJ Breast Cancer. 2021 Dec 1;7(1):150
pubmed: 34853355
Clin Cancer Res. 2021 Apr 1;27(7):1850-1854
pubmed: 33168656
Oncotarget. 2017 Feb 14;8(7):11708-11718
pubmed: 28052019
Microsyst Nanoeng. 2021 Jun 21;7:50
pubmed: 34567763
Oncol Lett. 2015 Sep;10(3):1233-1239
pubmed: 26622656
Clin Cancer Res. 2018 Jun 15;24(12):2804-2811
pubmed: 29559561
Cell. 2019 Nov 14;179(5):1191-1206.e21
pubmed: 31730857
Adv Drug Deliv Rev. 2017 May 15;114:43-59
pubmed: 28694027
Nat Rev Cancer. 2017 Aug;17(8):457-474
pubmed: 28706266
Immunoinformatics (Amst). 2021 Oct;1-2:
pubmed: 34708216
Front Immunol. 2020 May 21;11:924
pubmed: 32508825
Int J Mol Sci. 2021 Apr 29;22(9):
pubmed: 33946884
Physiol Rev. 2022 Oct 1;102(4):1837-1879
pubmed: 35771983
Sci Signal. 2020 Oct 06;13(652):
pubmed: 33023985
Cancer Sci. 2016 Jul;107(7):882-9
pubmed: 27145494
Cancer Immunol Immunother. 2020 Mar;69(3):435-448
pubmed: 31925475
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Nat Rev Cancer. 2021 May;21(5):298-312
pubmed: 33750922
Oncotarget. 2018 Jun 22;9(48):28989-29006
pubmed: 29989029
Trends Immunol. 2022 Jul;43(7):546-563
pubmed: 35690521
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
Nat Commun. 2021 Apr 12;12(1):2186
pubmed: 33846305
Breast Cancer Res Treat. 2014 Jul;146(1):211-20
pubmed: 24839032
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
Nat Commun. 2021 Aug 11;12(1):4867
pubmed: 34381029
Oncotarget. 2017 Dec 29;9(13):10945-10961
pubmed: 29541388
Cancer Sci. 2019 Jul;110(7):2080-2089
pubmed: 31102428
Cancer Sci. 2022 Jul;113(7):2457-2471
pubmed: 35441763
Signal Transduct Target Ther. 2021 Oct 7;6(1):362
pubmed: 34620838
Nat Rev Immunol. 2014 Jan;14(1):24-35
pubmed: 24336101
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Oncoimmunology. 2022 Jan 3;11(1):2020984
pubmed: 35003899
Cancer Discov. 2019 Aug;9(8):1102-1123
pubmed: 31197017
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Cell Sci. 2007 Jun 15;120(Pt 12):2053-65
pubmed: 17550972
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Cancer Res. 2013 Aug 1;73(15):4629-40
pubmed: 23722543
iScience. 2022 Jun 30;25(8):104702
pubmed: 35856032
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Nat Commun. 2020 Apr 3;11(1):1669
pubmed: 32245950
Front Oncol. 2022 Feb 14;12:772615
pubmed: 35237507
Cancer Res. 2022 Jun 15;82(12):2281-2297
pubmed: 35442423
Cancer Biol Ther. 2020 Jun 2;21(6):560-569
pubmed: 32213106
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Nat Cancer. 2021 Jan;2(1):66-82
pubmed: 33738458
Oncogene. 2021 Jul;40(27):4521-4537
pubmed: 34120141
N Engl J Med. 2022 Mar 24;386(12):1143-1154
pubmed: 35320644
Cell Cycle. 2012 Dec 1;11(23):4285-6
pubmed: 23095670
Cell. 2020 Mar 19;180(6):1081-1097.e24
pubmed: 32142650
EMBO J. 2014 May 16;33(10):1104-16
pubmed: 24737868
EMBO J. 2021 Jun 1;40(11):e107333
pubmed: 33950524
Nature. 2017 Apr 13;544(7649):250-254
pubmed: 28371798
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
J Clin Invest. 2020 Jun 1;130(6):3188-3204
pubmed: 32125284
Breast Cancer Res Treat. 2014 Apr;144(3):539-49
pubmed: 24596048
Nat Med. 2021 May;27(5):820-832
pubmed: 33958794
Cell Death Dis. 2018 Jan 11;9(1):14
pubmed: 29323124
J Mol Biol. 2017 Jun 2;429(11):1595-1606
pubmed: 28390900
J Leukoc Biol. 2019 Aug;106(2):309-322
pubmed: 30776148
Nat Immunol. 2018 Aug;19(8):885-897
pubmed: 30013147
Expert Opin Ther Targets. 2022 Jun;26(6):513-535
pubmed: 35761781
BMC Cancer. 2019 Mar 4;19(1):200
pubmed: 30832597
Cancer Res. 2012 Oct 15;72(20):5188-97
pubmed: 22836755
Front Cell Dev Biol. 2020 Aug 19;8:766
pubmed: 32974337
Annu Rev Physiol. 2019 Feb 10;81:505-534
pubmed: 30742782
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
PLoS Comput Biol. 2022 Jul 22;18(7):e1010254
pubmed: 35867773
J Breast Health. 2015 Apr 1;11(2):59-66
pubmed: 28331693
J Oncol. 2019 Jun 02;2019:5952836
pubmed: 31275382
Front Immunol. 2019 Aug 02;10:1835
pubmed: 31428105
Nat Commun. 2017 May 05;8:15081
pubmed: 28474673
Oncogenesis. 2021 Oct 5;10(10):66
pubmed: 34611125
Immunity. 2020 Jun 16;52(6):1075-1087.e8
pubmed: 32445619
Cell Commun Signal. 2022 Jun 17;20(1):92
pubmed: 35715860
J Leukoc Biol. 2012 Sep;92(3):673-82
pubmed: 22636320
Science. 2021 Dec 17;374(6574):abe6474
pubmed: 34914499
Nat Commun. 2018 Jul 24;9(1):2897
pubmed: 30042390
J Cell Biol. 2020 Sep 7;219(9):
pubmed: 32645139
Sci Rep. 2014 Jul 28;4:5853
pubmed: 25068296
Clin Cancer Res. 2004 Nov 15;10(22):7466-74
pubmed: 15569976
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Nat Cell Biol. 2019 Sep;21(9):1113-1126
pubmed: 31451770
Immunity. 2017 Nov 21;47(5):820-833
pubmed: 29166586
Cancer Cell. 2020 Jan 13;37(1):21-36.e13
pubmed: 31935371
FASEB J. 2018 Jan;32(1):276-288
pubmed: 28899878
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
Nat Chem Biol. 2021 Mar;17(3):326-334
pubmed: 33199915
Sci Rep. 2018 Mar 20;8(1):4899
pubmed: 29559701
Blood. 2017 Sep 21;130(12):1474-1477
pubmed: 28743715
Nat Commun. 2014 Sep 02;5:4715
pubmed: 25178650
Front Oncol. 2021 Mar 04;11:570623
pubmed: 33747906
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Lett. 2017 Jan 1;384:94-100
pubmed: 27693459
J Pathol Transl Med. 2019 May;53(3):180-187
pubmed: 30853706
Nat Genet. 2021 Sep;53(9):1334-1347
pubmed: 34493872
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
J Histochem Cytochem. 2012 Dec;60(12):963-75
pubmed: 22821552
NPJ Precis Oncol. 2021 Jun 29;5(1):62
pubmed: 34188163
Cancer Cell. 2021 Dec 13;39(12):1578-1593.e8
pubmed: 34653365
Breast Cancer Res. 2021 May 10;23(1):51
pubmed: 33966638
Expert Opin Ther Targets. 2020 Jun;24(6):559-572
pubmed: 32249708
Immunol Rev. 2021 Jan;299(1):74-92
pubmed: 33368346
Cell Death Discov. 2022 Mar 8;8(1):106
pubmed: 35260564
Proc Natl Acad Sci U S A. 2022 Apr 26;119(17):e2107394119
pubmed: 35439048
Oncoimmunology. 2020 May 14;9(1):1760685
pubmed: 32923118
Nat Rev Genet. 2022 Aug;23(8):505-518
pubmed: 35256818
Nat Commun. 2018 Sep 4;9(1):3588
pubmed: 30181541
Curr Oncol Rep. 2021 Mar 24;23(5):57
pubmed: 33763756
Onco Targets Ther. 2014 Aug 21;7:1475-80
pubmed: 25187727
Nat Rev Clin Oncol. 2021 Aug;18(8):527-540
pubmed: 33833434
Cell. 2019 May 16;177(5):1330-1345.e18
pubmed: 30982598
J Clin Oncol. 2015 Feb 1;33(4):304-11
pubmed: 25452441
Cancer Res. 2021 Aug 15;81(16):4290-4304
pubmed: 34224371
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
Mol Cancer. 2019 Mar 18;18(1):42
pubmed: 30885232
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34518219
EMBO J. 2020 Oct 1;39(19):e104063
pubmed: 32790115
Mol Cancer. 2020 Jun 20;19(1):107
pubmed: 32563252
Sci Rep. 2021 Jun 30;11(1):13590
pubmed: 34193879
Cancer Discov. 2020 Sep;10(9):1330-1351
pubmed: 32434947
Cancers (Basel). 2020 Aug 24;12(9):
pubmed: 32846967
Ann Oncol. 2020 Mar;31(3):387-394
pubmed: 32067680
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Nature. 2017 Sep 7;549(7670):101-105
pubmed: 28813417
Front Endocrinol (Lausanne). 2019 Jul 12;10:471
pubmed: 31354634
Cell Mol Immunol. 2010 May;7(3):182-9
pubmed: 20383174
Cancer Res. 2020 Mar 15;80(6):1342-1356
pubmed: 31969374
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cells. 2020 Jul 27;9(8):
pubmed: 32726950
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455670
Breast Cancer Res. 2020 Nov 11;22(1):124
pubmed: 33176887
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Cancers (Basel). 2021 Jul 10;13(14):
pubmed: 34298673
Oncogenesis. 2020 Oct 10;9(10):90
pubmed: 33040091

Auteurs

Natsuki Furukawa (N)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Vered Stearns (V)

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Cesar A Santa-Maria (CA)

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Aleksander S Popel (AS)

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH